Our Team
We are a mission-aligned team with expertise across human biology, immunology, chemistry, computational biology, data science, machine learning, drug development, clinical, and commercial leadership.
Our Purpose
We are drawn together by our shared purpose and relentless hunger to improve health outcomes for as many people as possible while reducing the growing chronic disease burden. Our approach to innovation is uniquely human-centered — unlocking connections between diverse untapped chemistry and biological pathways driving disease to create solutions preferred by patients and clinicians that are designed to transform the treatment of disease.
We have brought together an inclusive, interdependently ambitious, and high-performing team with the courage to learn, iterate and make leaps together. We approach our work with humility, acknowledging and embracing the complexity of the disciplines we need to bring together and the many unknowns in human biology. Given the scalability of our platform, we seek to be best in class collaborators with our industry partners to help rapidly advance as many therapies as possible to improve patient's lives.
Leadership
-
Margo Georgiadis
Co-Founder and CEO; Board DirectorLinkedIn -
Hok Hei Tam, Ph.D.
Co-Founder and CTOLinkedIn -
Lamya Shihabuddin, Ph.D.
CSOLinkedIn -
Kyle Chiang, Ph.D.
COOLinkedIn -
Christian Antoni
CMOLinkedIn -
John Mayfield
SVP, Business Development and StrategyLinkedIn -
Allison Bogosian
CPAOLinkedIn
Board of Directors
-
David Khougazian
Chairman of the BoardGrowth Partner, Flagship Pioneering -
Noubar Afeyan, Ph.D.
Co-Founder and Board DirectorFounder & CEO, Flagship Pioneering -
Margo Georgiadis
Co-Founder and CEO; Board Director -
André Andonian
Board DirectorChair of Asia Pacific and Strategic Advisor, Flagship Pioneering; Senior Partner Emeritus, McKinsey & Company. -
Andreas Fibig
Board DirectorFormer Chairman and CEO, International Flavors & Fragrances; Former Chairman and President, Bayer Healthcare Pharmaceuticals -
Larry Hamann
Board DirectorCo-founder and CEO of Interdict Bio; Former Global Head, Drug Discovery Sciences, Takeda Pharmaceuticals -
Ignacio Martinez
Co-Founder and Board DirectorGeneral Partner, Flagship Pioneering -
Michael Severino, M.D.
Board DirectorCEO, Tessera Therapeutics; Former Vice Chairman and President, Abbvie; Former SVP and CMO, Amgen -
Phyllis Yale
Board DirectorChair of the Board, Blue Cross Blue Shield of Massachusetts and Kindred Healthcare, Inc.; Board Member, Bristol-Myers Squibb; Former Senior Partner and Leader of Healthcare Practice, Bain & Company -
Pietro Antonio Tataranni, M.D.
Board ObserverChief Medical Officer, PepsiCo; Former SVP, Head of Medical Affairs, Diabetes and Cardiovascular, Sanofi
OUR SCIENTIFIC ADVISORY BOARD
-
Connor Coley, Ph.D.
Assistant Professor of Chemical Engineering & Electrical Engineering and Computer Science, MIT -
Jim Collins, Ph.D.
Termeer Professor of Medical Engineering & Science, MIT; Core Founding Faculty Member, Wyss Institute, Harvard; Institute Member, Broad Institute of MIT and Harvard -
Keith James, Ph.D.
Former President, Ferring Research Institute, and Senior Vice-President and Head of Drug Discovery at Insitro and Pfizer -
Iain McInnes, Ph.D., M.B.Ch.B
Vice Principal and Head of College of Medical, Veterinary and Life Sciences, Muirhead Chair of Medicine, Versus Arthritis Professor of Rheumatology, University of Glasgow -
Luke O'Neill, Ph.D.
Professor and Chair of Biochemistry and Immunology, Trinity College -
Paul Ridker, M.D.
Eugene Braunwald Professor of Medicine, Harvard University and Brigham and Women's Hospital; Director of the Center for Cardiovascular Disease Prevention -
Peter Sorger, Ph.D.
Otto Krayer Professor of Systems Pharmacology, Head of the Harvard Program in Therapeutic Sciences (HiTS), Harvard Medical School; Cofounder, Merrimack Pharmaceuticals
Join Us
Contact Us
-
Partnerships
We welcome the opportunity to partner with experts across areas who share our passion for creating Anthromolecule™ medicines and want to collaborate to accelerate the development of safe, efficacious and accessible therapies across diseases.
partnerships@montai.com -
Press
For media inquiries or the latest on research, thought leadership, company news, and events contact:
press@montai.com